CNS Pharmaceuticals Company Presentation

CNS pharmaceuticals 12 Planned U.S. Phase 2 Clinical Trial. • Final trial-design is presently being completed. • The CNS trial of Berubicin in adults is intended to be: • Adaptive : a trial design that allows for modifications to aspects of the design based on accumulating data from trial subjects • Randomized : randomly assigns patients into either the Berubicin group or the control group in order to eliminate bias and increase statistical significance • Controlled : including a control arm receiving standard of care in order to compare the effectiveness of Berubicin against the standard of care and to increase the statistical significance • Pivotal : designed to provide the data necessary for accelerated approval of the drug • The Polish Phase 2 trial for adults conducted by WPD is expected to provide additional statistical support to the Company’s US trial.